Results 191 to 200 of about 101,548 (353)

Changes in how people living with obesity perceive weight‐related discussions with their healthcare professional: Results from the cross‐sectional online ACTION‐DK 2022 and 2024 studies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study investigated changes in how people living with obesity (PwO) perceive weight‐related discussions with healthcare professionals (HCPs) in Denmark from 2022 to 2024, a period marked by shifts in obesity treatment options as well as the broader understanding of obesity.
Mette Bøgelund, Amanda F. Rasmussen, Pernille Andreassen, Per Nielsen, Signe Stensen, Jens M. Bruun   +5 more
wiley   +1 more source

Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity

Periodontology 2000, EarlyView., 2023
Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti, Jean E. Suvan, Francesco D'Aiuto   +2 more
wiley   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

Rethinking control‐IQ+ technology: Simple strategies for easy optimization

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Control‐IQ+ is an automated insulin delivery (AID) algorithm approved for people with type 1 diabetes aged 2+ years and adults aged 18+ years with type 2 diabetes. While numerous publications support improved glycaemia and quality of life for people with diabetes, this practice paper is intended to encourage uptake for healthcare professionals
Viral N. Shah, Pratik Choudhary, Ilana Halperin, Ivana Rabbone, Dessi P. Zaharieva, Laurel Messer   +5 more
wiley   +1 more source

Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer

Clinical Endocrinology, EarlyView.
Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert, The UK Thyroid Cancer Study Group   +4 more
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. [PDF]

Diabetes Obes Metab
Vilsbøll T, Stellfeld M, Aroda VR, Dandanell S, David JP, Kristiansen CTP, Rasmussen S, Roberts FL, Hegedüs L.   +8 more
europepmc   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention. [PDF]

J Cosmet Dermatol
Kruglikov IL.
europepmc   +1 more source

Glucagon-like peptide-1 receptors agonists (GLP1 RA).

JPMA. The Journal of the Pakistan Medical Association, 2014
The glucagon-like peptide-1 receptors agonists (GLP1RA) are a relatively new class of drugs, used for management of type 2 diabetes. This review studies the characteristics of these drugs, focusing upon their mechanism of action, intra-class differences, and utility in clinical practice.
openaire   +1 more source